Immuron (IMRN) Non-Current Assets (2015 - 2026)
Immuron (IMRN) posted Non-Current Assets of $192721.0 for Q3 2026, up 68.14% on a QoQ basis from $114616.0 in Q4 2025, and up 16714.49% year-over-year from N/an in Q3 2025.
Analysis
Immuron (IMRN) Non-Current Assets (2015 - 2026) Analysis & Trends
Immuron has reported Non-Current Assets for 12 years, with the latest figure at $192721.0 in Q3 2026.
- On a quarterly basis, Non-Current Assets rose 16714.49% year-over-year to $192721.0 in Q3 2026; TTM through Aug 2026 was $381887.1, a 123.99% increase from a year earlier, with the FY2026 full-year figure at $192721.0, up 16714.49% from the prior year.
- Non-Current Assets was $192721.0 for Q3 2026 at Immuron, up from $114616.0 in the prior quarter.
- The five-year high for Non-Current Assets was $1.1 million in Q2 2023, with the low at -$16.5 million in Q3 2022.
- Average Non-Current Assets over 5 years is -$4.1 million, with a median of $3317.2 recorded in 2024.
- The sharpest annual moves came in 2025 and 2026: Non-Current Assets tumbled 86.48% in 2025, then jumped 16714.49% in 2026.
- Over 5 years, Non-Current Assets stood at -$15.4 million in 2022, then advanced by 14.57% to -$13.2 million in 2023, then jumped by 87.29% to -$1.7 million in 2024, then jumped by 106.86% to $114616.0 in 2025, then surged by 68.14% to $192721.0 in 2026.
- The last three Non-Current Assets figures came in at $192721.0 (Q3 2026), $114616.0 (Q4 2025), and $1146.2 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 60.68 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 35.42 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 14.88 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 23.28 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 1.96 Bn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 5.15 Bn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 938.60 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 24.78 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | 564.41 Mn |
| 10 | Immuron | 10.28 Mn | 1.26 Mn | - | 192,721.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Aug 28, 2026 | 192,721.00 |
| Dec 31, 2025 | 114,616.00 |
| Sep 2, 2025 | 1,146.16 |
| Jun 30, 2025 | 73,403.89 |
| Dec 31, 2024 | -1.67 Mn |
| Sep 9, 2024 | 5,488.15 |
| Jun 30, 2024 | 542,793.65 |
| Dec 31, 2023 | -13.16 Mn |
| Sep 28, 2023 | -13.38 Mn |
| Aug 30, 2023 | -204,093.37 |
| Jun 30, 2023 | 1.06 Mn |
| Dec 31, 2022 | -15.40 Mn |
| Aug 31, 2022 | -16.46 Mn |
| Jun 30, 2022 | 847,826.76 |
| Dec 31, 2021 | -18.67 Mn |
| Sep 30, 2021 | -18.94 Mn |
| Jun 30, 2021 | 1.00 Mn |
| Dec 31, 2020 | 2.80 Mn |
| Sep 1, 2020 | 1.61 Mn |
| Jun 30, 2020 | 1.18 Mn |